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Graft-vs.-host disease (GvHD) is a major complication after allogeneic hematopoietic
stem cell transplantation that causes mortality and severe morbidity. Genetic disparities
in human leukocyte antigens between the recipient and donor are known contributors to
the risk of the disease. However, the overall impact of genetic component is complex,
and consistent findings across different populations and studies remain sparse. To gain
a comprehensive understanding of the genes responsible for GvHD, we combined
genome-wide association studies (GWAS) from two distinct populations with previously
published gene expression studies on GvHD in a single gene-level meta-analysis. We
hypothesized that genes driving GvHD should be associated in both data modalities
and therefore could be detected more readily through their combined effects in the
integrated analysis rather than in separate analyses. The meta-analysis yielded a total
of 51 acute GvHD-associated genes (false detection rate [FDR] <0.1). In support
of our hypothesis, this number was significantly higher than that in a permutation
meta-analysis involving the whole data set, as well as in separate meta-analyses on
the GWAS and gene expression data sets. The genes indicated by the meta-analysis
were significantly enriched in 277 Gene Ontology terms (FDR < 0.05), such as T
cell function and cytokine-mediated signaling pathways, and the results highlighted
several established immune mediators, such as interleukins and JAK-STAT signaling,
and presented TRAF6 and TERT as potential effector candidates. Altogether, the results
support the chosen methodological approach, implicate a role of gene-level variation in
donors’ key immunological regulators predisposing patients to acute GVHD, and present
potential targets for therapeutic intervention.
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INTRODUCTION
Allogeneic hematopoietic stem cell transplantation (HSCT) is
utilized as a curative treatment for life-threatening hematological
malignancies. Despite improvements in survival and reduced
morbidity over time, graft- vs.-host disease (GvHD) remains a
major severe complication of HSCT (1). In the early stages of the
treatment, donor T cell-mediated alloimmune reactions against
the recipient’s tissues give rise to acute GvHD (aGvHD), and
consequently the majority of GvHD prophylaxis is directed at
reducing aGvHD. Conditioning leads to gastrointestinal track-
derived diffusion of microbial antigens, which, in turn, induces
extensive immune activation and cytokine storm (2). However,
the immune pathology of chronic GvHD (cGvHD) more closely
resembles the symptoms of common autoimmune diseases
involving dysregulation of immune tolerance and chronic tissue
damage (3).
The success of HSCT treatment is strongly influenced by
genetic disparities between the recipient and donor (4). The
best characterized are classical human leukocyte antigen (HLA)
genes encoded within the human major histocompatibility
complex (MHC) on chromosome 6. Mismatching recipient and
donor for HLA-molecules is a well-established risk factor for
GvHD and overall survival (5, 6). However, both HLA and
minor histocompatibility antigen disparities have been shown
to result in the beneficial graft- vs.-leukemia effect reducing
the risk of relapse (7, 8). Emphasizing the complex genetic
background of the condition, the susceptibility to GvHD is also
potentially altered by donor or recipient polymorphisms in genes
involved in immune responses (9–11) and drug metabolism
(12, 13), common deletions (14), and regulatory elements (15).
Nevertheless, owing to the lack of replication of many of the
results in large independent cohorts, a full understanding of
relevant genetic factors remains elusive.
The first genome-wide association studies (GWASs) onGvHD
were published by Sato-Otsubo et al. (16) and Bari et al. (17) in
2015. Sato-Otsubo et al. studied unrelated HSCT in a Japanese
population and identified an association between HLA-DPB1
allele disparity and aGvHD. Additionally, they discovered three
novel loci, including one in HLA-DP region, linked to severe
aGvHD. Bari et al. identified recipient SUFU rs17114808 as a
susceptibility locus for aGvHD in a cohort of US children (17).
However, this result was not replicated in German pediatric and
adult cohorts (18). In 2017, Goyal et al. reported three HLA-DP
region loci in recipient genomes associated with severe aGvHD in
a population with European-American ancestry (19). A genome-
wide approach was also employed by Martin et al. (20) and
Ritari et al. (21, 22), who both studied the effect of genome-wide
recipient-donor mismatching. They concluded that an increase
in genome-wide recipient mismatching is associated with an
increased risk for GvHD.
The incomplete understanding of molecular mechanisms of
GvHD-pathology and the shortage of solid biomarkers have
prompted studies on GvHD-related gene expression. Donor
gene expression profiling was utilized to detect “stronger
alloresponders” by Baron et al. (23) in 2007, and in 2008, Buzzeo
et al. (24) reported the first preliminary molecular signature of
aGvHD. In 2015, Furlan et al. suggested that the recipient T
cell transcriptional profile could be employed in identification
of novel therapeutics, and aurora kinase A was presented as a
potential target (25).
We hypothesized that combining different data sets and types
could enhance the ability to detect weak but systematic common
gene-level effects underlying GvHD-pathogenesis. In our present
study, we explore the cooperative relationship between GWAS
signals mapped into genes and published gene expression profiles
in aGvHD and cGvHD. We carried out GWAS on Finnish and
Spanish sibling HSCT cohorts and integrated these data with
donor gene expression data sets by a meta-analysis based on
gene rankings. We sought to determine whether the two data
modalities lend support to each other and to understand the
functional categories that may explain the outcome of HSCT in
terms of GvHD pathogenesis.
MATERIALS AND METHODS
Study Cohorts
The study consisted of three HLA-matched sibling cohorts
including two populations: Finnish Cohort 1, Spanish Cohort 1,
and Finnish Cohort 2. The characteristics of these study cohorts
are presented in Table 1.
Finnish Cohort 1 and Spanish Cohort 1 have been described
previously in detail (11). Briefly, Finnish Cohort 1 consisted
of 239 donor-recipient pairs, 23 individual recipients, and 28
individual donors with available clinical data and imputed
genotype. All recipients received related donor (RD)-HSCT
from 1993 through 2006 at Helsinki University Hospital,
Comprehensive Cancer Center, Stem Cell Transplantation Unit,
Finland. Spanish Cohort 1 was composed of 253 donor-recipient
pairs, 15 individual recipients, and 30 individual donors with
available clinical data and the imputed genotype. The recipients
received RD-HSCT from 2002 through 2014 at 13 Spanish
transplant centers. HLA-matching was performed at the HLA-
A, -B, and -DRB1 loci in both cohorts.
Finnish Cohort 2 included 171 donor-recipient pairs, 3
individual recipients, and 1 individual donor with clinical data
and an imputed genotype. RD-HSCT was implemented at two
Finnish centers: Helsinki University Hospital, Comprehensive
Cancer Center, Stem Cell Transplantation Unit and Turku
University Central Hospital during the years 2006–2016. HLA-
matching was performed at the HLA-A, HLA-B, HLA-C, and
HLA-DRB1 loci (21).
The included clinical outcomes were grades 0, II–IV and
III–IV for aGvHD, and grades 0, limited, and extensive for
cGvHD. Grading was determined locally according to the
European Society for Blood and Marrow Transplantation
guidelines (26, 27).
The study conformed to the principles of the Declaration of
Helsinki and was approved by the Finnish National Supervisory
Authority for Welfare (Dnro V/74832/2017, V/3235/2019) and
Health and the ethics committees of Helsinki University
Central Hospital (382/13/03/01/2014, HUS/114/2018) and Turku
University Central Hospital (ETMK 78/2012). Samples and data
from Spanish patients included in this study were provided by
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TABLE 1 | Characteristics of the study cohorts.
Finnish Cohort 1a Spanish Cohort 1b Finnish Cohort 2c P
Number of recipients 262 268 174
Number of donors 267 283 171
Recipient age, median years (range) 48 (18–65) 50 (8–72) 51 (12-69) 0.021d
Donor age, median years (range)e 47 (11–68) 49 (4–78) 50 (11–72) 0.020d
Direction of transplantation, n (%) 0.674f
Male-male 73 (28) 87 (33) 35 (20)
Male-female 57 (22) 62 (23) 32 (18)
Female-female 61 (23) 51 (19) 29 (17)
Female-male 71 (27) 66 (25) 41 (24)
Diagnosis, n (%)
Acute myeloid leukemia 73 (28) 88 (33) 59 (34) 0.312f
Acute lymphoblastic leukemia 39 (15) 24 (9) 21 (12) 0.112f
Chronic myeloid leukemia 37 (14) 13 (5) 8 (5) <0.001f
Myelodysplastic syndrome 20 (8) 26 (10) 18 (10) 0.566f
Hodgkin’s lymphoma 0 (0) 12 (5) 1 (1) NAg
Non-Hodgkin’s lymphoma 12 (5) 50 (19) 6 (3) <0.001f
Myeloma 56 (21) 38 (14) 24 (14) 0.043f
Aplastic anemia 4 (2) 5 (2) 1 (1) NAg
Other malignancies 21 (8) 11 (4) 37 (21) <0.001f
Stem cell source, n (%) <0.001f
Bone marrow 138 (53) 13 (5) 58 (33)
Peripheral blood 124 (47) 254 (95) 116 (67)
Conditioning regimen, n (%) <0.001f
Myeloablative 199 (76) 110 (41) 132 (77)
Reduced intensity conditioning 63 (24) 151 (57) 40 (23)
GvDH prophylaxis, n (%) NAg
Cyclosporine + methotraxate 0 (0) 151 (57) 76 (44)
Cyclosporine 0 (0) 27 (10) 9 (5)
Cyclosporine + methotraxate +steroid 193 (74) 0 (0) 68 (39)
Cyclosporine + mycophenolate mofetil 50 (19) 31 (12) 4 (2)
Other or missing data 18 (7) 58 (22) 17 (10)
aGvHD grades II–IV, n (%) 42 (16) 94 (35) 67 (39) <0.001f
aGvHD grades III–IV, n (%) 23 (9) 39 (15) 35 (20) 0.001 f
cGvHD limited-extensive, n (%) 130 (54) 82 (41) 100 (58) <0.001f
cGvHD extensive, n (%) 71 (39) 54 (32) 77 (45) <0.001f
aGvHD, acute graft- vs.-host disease; cGvHD, chronic graft- vs.-host disease; NA, not applicable.
aFinnish recipients underwent related donor (RD)-HSCT at Helsinki University Hospital, Comprehensive Cancer Center, Stem Cell Transplantation Unit, Finland, between 1993 and 2006.
bSpanish recipients underwent RD-HSCT at 13 Spanish transplant centers between 2002 and 2014.
cFinnish recipients underwent RD-HSCT at two Finnish centers: Helsinki University Hospital, Comprehensive Cancer Center, Stem Cell Transplantation Unit and Turku University Central
Hospital between 2006 and 2016.
dThe significance of variation between characteristics in the study cohorts was analyzed using the non-parametric Kruskal-Wallis test.
eDue to the missing data, approximately 20% of donor ages were imputed based on the respective recipient’s age in the Spanish Cohort 1.
fThe significance of variation between characteristics in the study cohorts was analyzed using the Pearson chi-square test.
gThe significance of variation between characteristics in the study cohort was not analyzed due to the low frequency counts.
the IDIBGI Biobank (Biobanc IDIBGI, B.0000872), integrated in
the Spanish National Biobanks Network, and they were processed
following standard operating procedures with the appropriate
approval of the ethics and scientific committees.
Genotyping and Imputation
The genotyping and imputation procedures have been previously
described in detail (11). Briefly, Finnish Cohort 1 was genotyped
using an Illumina Immunochip and Spanish Cohort 1 and
Finnish Cohort 2 with Illumina were genotyped with an
Immunoarray v2.0. Imputation of autosomal genotype data
was performed using IMPUTE2 and the 1000 Genomes Phase
3 reference (28). Quality filtering for variants and samples
was performed according to Anderson et al. (29), and an
IMPUTE2 INFO-field measure ≥0.5 was used as the cut-off for
post-imputation filtering (30). The three datasets were filtered
and imputed in separate processes, and the final number of
variants included in the analyses was 5041081 for Finnish
Cohort 1, 5737173 for Spanish Cohort 1, and 9105726 for
Finnish Cohort 2.
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Statistical Analysis of the Characteristics
of the Study Cohorts
The significance of differences in recipient and donor age
among the three study cohorts was analyzed using the non-
parametric Kruskal–Wallis test. Pearson’s chi-square test was
used to evaluate the frequencies of diagnosis, gender direction
of transplantation, stem cell source, conditioning regimen, and
GvHD grades. Due to low frequency, the variation in Hodgkin’s
lymphoma and aplastic anemia diagnosis were not analyzed. The
significance level of tests (alpha level) was set at 0.05.
Population Structure Inference and
Logistic Regression Analysis of the
Covariates
The population structures were determined using principal
component (PC) analysis (PCA). The analysis was implemented
with PLINK 1.90b4.1 (www.cog-genomics.org/plink/1.9/) (31).
Genotyped variants shared by all three cohorts were pruned to
generate a subset of variants in approximate linkage equilibrium
(–indep-pairwise 50 5 0.5). Dimensional reduction was executed
with the command –pca and the top 20 PCs for each
cohort were extracted separately. The combined data were
used to generate a scatterplot matrix of the five initial PCAs
[Supplementary Figure 1 (Supplementary Data Sheet 1)]. The
plot was generated using R version 3.5.0.
Logistic regression analysis (PLINK command –logistic) was
employed to investigate the effect of baseline covariates on
the GvHD-related outcome. Binary aGvHD or cGvHD status
was used as a dependent variable, and recipient gender,
recipient age, direction of transplantation, and stem cell source
were included as independent variables [Supplementary Table 1
(Supplementary Data Sheet 1)]. The results are presented as
odds ratios (ORs) with 95% confidence intervals (CIs), and a
P-value <0.05 was considered statistically significant.
GWAS
In the preliminary analysis, the associations between recipient
and donor genotypes and GvHD clinical outcomes were
examined using the PLINK 1.07 (32) 1df chi-square allelic test
(command –assoc) and are expressed as odds ratios with 95%
confidence intervals. Variants with a minor allele frequency
<0.01, Hardy-Weinberg disequilibrium P-value <1 × 10−5, and
missing call rate >0.1 were excluded from the analysis. After
correction for multiple testing, a genome-wide P-value <1 ×
10−7 was considered statistically significant.
For the adjusted analyses, the association between variants
and clinical outcomes was determined using PLINK 1.90b4.1 (31)
logistic regression analysis (command –logistic). Variant filtering
followed the previously described practice. For all recipients,
recipient gender, recipient age, graft type, and the first three
cohort specific PCs were used as covariates. For the donors,
donor gender, donor age, graft type, and the first three PCs
were used as covariates. The donor age data were incomplete
in Finnish Cohort 1 and Spanish Cohort 1, and the missing
data were imputed using the corresponding recipient’s age using
linear regression.
Meta-Analyses
The Figure 1A presents a schematic diagram of the main steps
of the analysis pipeline. The SNP associated P-values of donor
aGvHD grades II–IV vs. 0 and cGvHD limited-extensive vs. 0
GWASs from all three study cohorts were mapped into genes
usingMAGMA (33) v1.07b (https://ctg.cncr.nl/software/magma)
with the default 1000 Genomes GRCh37 LD data and gene
annotation data provided with MAGMA.
GvHD-related gene expression (GE) data sets (23–
25, 34–39) were retrieved from the Gene Expression
Omnibus data repository (https://www.ncbi.nlm.nih.gov/
geo/). A summary of the selected GE studies is presented in
the Supplementary Table 2 (Supplementary Data Sheet 1).
Analysis of differential expression in the GE data sets was
conducted using the R package limma v3.38.3 functions lmFit
for fitting linear models, and eBayes to determine the empirical
Bayes moderated standard errors of the models.
Using the gene lists obtained from the GWAS and GE
analyses, we conducted three independent meta-analyses: (1) the
GWASs together, (2) the GE studies together, and (3) the GWASs
and the GE studies combined, for both the aGvHD and cGvHD
data sets. These analyses were executed using the robust rank
aggregation (RRA) method (40) implemented in the R package
RobustRankAggreg v1.1 function aggregateRanks using exacted
P-value calculations. Genes with a false discovery rate (FDR)
<0.1 were considered significant and included in the downstream
analyses for gene ontology (GO) biological processes (BP)
enrichment. GO:BP enrichment was performed using the R
package clusterProfiler (41) v3.10.1 function enrichGO with the
full list of analyzed genes as the background set. GO terms with
an FDR < 0.05 were considered statistically significant.
To control for subtle biases that could potentially cause
inflated numbers of false positives, we conducted permutation
tests on the gene lists included in the RRA meta-analysis. The
gene list permutation was repeated 100 times, and for each
iteration, the number of genes with an FDR < 0.1 was calculated.
These values were then compared with the numbers of significant
genes from the RRA conducted on the original gene lists to
estimate whether the observed number of significant genes could
be obtained by chance alone.
A similar permutation test was conducted for the GO:BP
enrichment analysis, whereby the enrichment at an FDR < 0.05
was re-calculated for each iteration of the permutated RRA for
genes with an FDR < 0.1. Each enriched gene combination was
accepted only once to limit the number of redundant GO terms.
The clustering and visualization of the GO enrichment results
were performed using the REVIGO (42) Web server (http://
revigo.irb.hr/).
Visualization of Colocalization of GWAS
and eQTL Events
The visualization of colocalization of GWAS and expression
quantitative trait loci (eQTL) events was performed using
the R package LocusCompareR (43). The GWAS variants of
aGvHD-associated genes were selected using a ± 1Mb range
from the gene boundaries. The corresponding blood cis-eQTL
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FIGURE 1 | Overview of the study setup and associated genes. (A) Schematic diagram showing the main steps of the analysis pipeline. (B) Manhattan plot of donor
aGvHD meta-analysis results. The meta-analysis includes the donor GWAS II–IV vs. 0 results from Finnish Cohort 1, Spanish Cohort 1, Finnish Cohort 2, and six
previously published aGvHD gene expression studies. The analysis was conducted as depicted in the Method section. The red line indicates a false detection rate of
<0.1.
SNPs were extracted from the eQTLGen Consortium database
(http://www.eqtlgen.org) (44). This database incorporates 31,684
individuals and 37 datasets, resulting in 16,989 cis-eQTL genes.
The generated plots visualized the distributions of cis-eQTL
and GWAS signals and the linkage disequilibrium to the
selected variant.
Gene Expression Directions
To visualize the direction and distribution of expression of the
significant RRA genes, the gene-wise expression values were
extracted from each included GE study. For each study, the
expression values for the cases were divided by the mean value
of the controls and thereafter scaled by subtracting the mean and
dividing by the standard deviation. The processed values were
then pooled for each gene from all of the GE studies and plotted
as boxplots.
Data and Code Availability Statement
The limitations of ethical permits restrict the public distribution
of personal data including individual genetic data. The code for
the meta-analyses is publicly available in GitHub (https://github.
com/FRCBS/GvHD_meta).
Supplemental Information
The supplementary information includes
Supplementary Data Sheets 1–4.
RESULTS
Characteristics of the HSCT Study Cohorts
and the GvHD-Related Risk Factors
Table 1 summarizes the key characteristics of the HSCT study
cohorts. The three cohorts differed substantially in many
aspects. The distributions of recipient and donor ages and
the frequencies of diagnoses, stem cell sources, conditioning
regimens, and GvHD outcomes significantly varied among the
cohorts. Additionally, the GvHD prophylaxis regimens varied
markedly. The association between the common GvHD-related
risk factors and the disease outcomes diverged as depicted
in Supplementary Table 1 (Supplementary Data Sheet 1).
Increasing recipient age was significantly associated with all
GvHD outcomes in Finnish Cohort 1 (all P-values ≤ 0.036).
However, the odds ratios were low (from 1.035 to 1.087) and
age had no effect in the other two study cohorts. Female gender
was associated with beneficial cGvHD outcomes in Spanish
Cohort 1 (P-values = 0.001). Using the bone marrow as a stem
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cell source reduced the risk for both aGvHD and cGvHD in
Finnish Cohort 2 (P-values ≤ 0.045, except for 0.065 in the
cGvHD limited-extensive group) and for cGvHD in Finnish
Cohort 1 (P-values ≤ 0.007).
GWASs of the HSCT Study Cohorts
In the unadjusted preliminary GWAS in Finnish Cohort 1,
we found severe aGvHD-associated loci in the MHC region
in the recipient genotype at a genome-wide significance level
of P < 5 x 10−8 and in the donor genotype at a suggestive
significance level of P <5 × 10−5 [Supplementary Figure 2
(Supplementary Data Sheet 1), panel A for recipients and panel
C for donors]. These results were not replicated in the two
other HSCT study cohorts, and none of the variants reached a
genome-wide significance level (data not shown). Additionally,
all genome-wide significance was abolished in Finnish Cohort
1 after adjusting the analyses by recipient age, recipient gender,
stem cell source, and the top three PCs [Supplementary Figure 2
(Supplementary Data Sheet 1), panel B for recipients and D
for donors].
Meta-Analyses
All data sets included in the RRA meta-analyses are presented
in Table 2, and more detailed information on the GE studies
performed is listed in Supplementary Table 2 (Supplementary
Data Sheet 1). The combined meta-analysis of cGvHD-related
data sets revealed only cysteine protease legumain (LGMN) as
associated with cGvHD at the FDR < 0.1 level. The analysis of
aGvHD-related data sets revealed 51 aGvHD-associated genes
at the FDR < 0.1 level, including lymphotoxin beta receptor
(LTBR), Janus kinase 1 (JAK1), tumor necrosis factor (TNF)
receptor associated factor 6 (TRAF6), signal transducer and
activator of transcription 1 (STAT1), vitamin D receptor (VDR),
interleukin (IL) 11, IL15, and IL1 receptor 2 (IL1R2) [Figure 1;
Supplementary Table 3 (Supplementary Data Sheet 1)]. The
GO enrichment analysis of these genes detected 277 aGvHD-
associated BPs at the FDR < 0.05 level [Supplementary Table 4
(Supplementary Data Sheet 1)]. The majority of associated
GO:BP categories were strongly linked to immune responses
and regulation, highlighting T cell function and cytokine-
mediated signaling pathways. The top 30 of these detailed GO:BP
categories are presented in Figure 2A. The degree of relatedness
of all ontological categories defined by their annotation, the
sematic similarity, is shown in Figure 2B.
To confirm the validity of the combined meta-analysis
including both the GWASs and the GE studies, we performed
a meta-analysis of the GWASs and the GE studies separately.
Figure 3A presents the comparison of aGvHD-associated genes
and unique GO:BP gene combinations in different analysis
settings. The meta-analysis of the three GWASs did not result in
any associated genes at the FDR < 0.1 level and, consequently,
no GO:BPs at the FDR < 0.05 level. We found two genes and
three GO:BPs associated with aGvHD in the separate GE meta-
analyses, but these numbers were substantially lower than those
in the combined meta-analysis (51 genes and 156 unique GO:BP
gene combinations).
The mean number of significant (FDR < 0.1) permuted RRA
genes was 5.69 with an SD of 0.48, which corresponded with the
TABLE 2 | The data sets included in the aGvHD and cGvHD meta-analyses.
Meta-
analysis
GWAS Gene expression studya
(GEO number)
aGvHD Finnish Cohort 1 donors aGvHD
II–IV vs. 0
GSE4624
GSE75344
GSE103569
GSE73809
GSE10572
GSE7510
Spanish Cohort 1 donors aGvHD
II–IV vs. 0
Finnish Cohort 2 donors aGvHD
II–IV vs. 0
cGvHD Finnish Cohort 1 donors cGvHD
limited-extensive vs. 0
GSE4624
GSE56495
GSE60674
GSE23924
Spanish Cohort 1 donors cGvHD
limited-extensive vs. 0
Finnish Cohort 2 donors cGvHD
limited-extensive vs. 0
aGvHD, acute graft- vs.-host disease; cGvHD, chronic graft- vs.-host disease; GEO, gene
expression omnibus; GWAS, genome-wide association study.
ahttps://www.ncbi.nlm.nih.gov/ge.
expected number of 5.1 based on an FDR< 0.1 in the true data. In
the GO enrichment analysis of permuted data, the mean number
of significant (FDR< 0.05) unique GO terms was 7.95 with an SD
of 1.28, which was also close to the expected value of 7.8 obtained
from the true data at an FDR < 0.05. The number of significant
genes or GO terms did not reach the value obtained with the true
data in any of the permutation iterations. Figure 3B depicts the
results of the permutation tests.
Colocalization of GWAS and eQTL Events
and the Combined Effect Directions of
Gene Expression Studies
The colocalization of GWAS and cis-eQTL events of
the 51 aGvHD-associated genes were visualized using
LocusCompareR and the results for Finnish Cohort 1,
Spanish Cohort 1, and Finnish Cohort 2 are presented in
Supplementary Data Sheets 2–4, respectively. The majority
of events showed no direct positive colocalization signal.
However, the cis-eQTL events of TRAF6 and the corresponding
variants of aGvHD GWASs were colocalized in Finnish
Cohort 1 (Figure 4A). This observation was supported by
Spanish Cohort 1, although the lead variants were independent
(Figure 4B). We formulated combined effect directions of
gene expression for the 51 aGvHD-associated genes from
the aGvHD GE data sets (Figure 5). The expression levels
of TRAF6, TRAF3, IL1R2, interferon induced protein with
tetratricopeptide repeats 5, and bone morphogenetic protein 6
seemed to be reduced among the aGvHD patients compared to
the controls.
Data and Code Availability
The limitations of ethical permits restrict the public distribution
of personal data including individual genetic data. The code for
the meta-analyses is publicly available in GitHub (https://github.
com/FRCBS/GvHD_meta).
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FIGURE 2 | Visualization of enrichment and sematic similarity of the aGvHD-associated gene ontologies. The aGvHD-associated genes discovered in the
meta-analysis were analyzed for enriched Gene Ontology Biological Process (GO:BP) categories. (A) T cell activation and cytokine response-focused GO:BP
categories. The X-axis shows the enrichment level, and the size of the circle depicts the false detection rate (FDR). (B) Sematic similarity analysis of all the GO:BP
categories. The bubbles represent the individual GO:BP categories, and more related terms are closer in the plot. The uniqueness from the total mean is shown by a
color scale, with blue indicating a less unique and red indicating a more unique category. The size of the circle indicates the number of detected genes within the
underlying GO term. The labels present some of the cluster representatives.
FIGURE 3 | Validation of the aGvHD meta-analysis. (A) Results of meta-analyses on the GWAS and GE studies separately and the meta-analysis on the GWAS and
GE data together. The left side panel shows the number of associated genes at a false detection rate (FDR) level of <0.1, and the right side panel shows the number
of Gene Ontology biological process (GO:BP) categories at an FDR < 0.05. (B) Results of 100 meta-analyses with permuted gene order. The left side panel shows the
numbers of aGvHD-associated genes at an FDR level of <0.1, and the right side panel shows the numbers of GO:BP categories at an FDR level of <0.05. The vertical
red line depicts the corresponding values from the original meta-analysis. The meta-analyses include the donor GWAS II–IV vs. 0 results from Finnish Cohort 1, Spanish
Cohort 1, Finnish Cohort 2, and six previously published aGvHD gene expression (GE) studies. The analyses were conducted as described in the Methods section.
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DISCUSSION
In this study, we performed a novel gene-level meta-analysis
on GvHD by integrating GWAS data and gene expression
results from different populations and study settings. We
discovered pathways associated with aGvHD pathogenesis,
implicating immunological responses in processes such as T cell
function, cytokines, JAK-STAT signaling, and regulation of the
TRAF6 gene.
The risk for GvHD has mainly been investigated during
past decades by concentrating on the MHC region and specific
candidate genes (10, 11), and only in recent years has the use
of genome-wide approaches emerged in the field (16, 17, 19–22).
These studies have shown the importance of genetic component
in HSCT complications, but the results remain diverse, and
their replication is incomplete. Even though individual gene
expression studies can yield several differentially expressed
genes, the dynamic nature of gene expression and heterogeneity
in the treatment settings and genetic and environmental
backgrounds of the subjects may make generalization from a
single study difficult. Additionally, interpreting the functionality
and downstream effects of disease-associated GWAS variants
has generally been problematic because the majority of detected
polymorphisms fall within non-coding regions of the genome.
Our results highlight the strength of extensive meta-analysis;
neither the independent adjusted GWASs nor the separate
meta-analyses of gene expression or GWAS yielded statistically
significant results alone. In contrast, the full data combination
produced biologically meaningful genes and biological processes
that were confirmed by permutation analysis. Thus, these results
may indicate genes that have an impact on GvHD regardless of
the various differences between the cohorts.
In the present study, the 51 aGvHD-associated genes included
several prominent immunological effectors, supporting their
role in GvHD pathogenesis. Many of these genes have been
linked with GvHD in previous studies [Supplementary Table 5
(Supplementary Data Sheet 1)]. Connection with aGvHD has
been demonstrated for telomerase reverse transcriptase (TERT),
IL11, IL15, Kruppel like factor 2 (KLF2), STAT1, interferon
regulatory factor 5 (IRF5), histone deacetylase 4 (HDAC4), JAK1,
receptor interacting serine/threonine kinase 1 (RIPK1), TRAF3,
and TRAF6 (45–58). As most of these genes have been studied
mainly in murine models, their detection by our meta-analysis
supports the role of these immune effectors in humans, and
therefore provides candidates for potential drug targets. For
instance, HDAC inhibitor Vorinostat has been shown to be
promising in phase I/II trials (28784598).
Many of the implicated genes are parts of key
immunoregulatory pathways such as JAK-STAT, TNF, and
nuclear factor kappa B (NFκB). JAK1, an essential kinase for
cytokine receptor signaling molecules, and STAT1, an activating
transcription factor in response to pathogens, were involved
in 33% of the significantly enriched biological processes.
Importantly, JAK-STAT signaling assembles a connective
molecular mechanism for multiple observations involving
IL11, IL15 and other cytokines and links these results to the
aGvHD-predisposing cytokine storm. Currently, the JAK1/2
FIGURE 4 | Colocalization of aGvHD GWAS and eQTL events of TRAF6 in
Finnish Cohort 1 and Spanish Cohort 1. Visualization of colocalization events
was performed using LocusCompareR as described in the Methods section.
The cis-eQTL P-values of the TRAF6 locus were extracted from the eQTLGen
Consortium database (http://www.eqtlgen.org) and the aGvHD-related
P-values were obtained from the donor GWAS II–IV vs. 0 results. The dots in
the scatter plots are colored according to their linkage disequilibrium to the
colocalization lead variant. (A) Shows the colocalization of the eQTL and
GWAS distributions of TRAF6 in Finnish Cohort 1, and (B) shows these
distributions in Spanish Cohort 1.
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FIGURE 5 | Direction and distribution of expression of aGvHD-associated genes. The effect directions were derived from all aGvHD-linked gene expression studies as
described in the Methods section. The box plots represent the interquartile range (IQR) with the median, and the whiskers represent a maximum IQR of 1.5. The
X-axis depicts the normalized distribution of gene expression values of cases relative to the mean of controls. SD, standard deviation.
inhibitor ruxolitinib is considered a potent salvage therapy
for corticosteroid-refractory GvDH (59) and is being studied
in a prospective randomized phase 2 trial (NCT02396628).
The role of TNF signaling was also evident in the results; the
herpesvirus entry mediator (HVEM), a member of the TNF
receptor superfamily, is expressed on T-cells, and soluble LTBR
protein has been shown to compete with HVEM receptor to
inhibit T-cell activity and prevent GvHD in murine models.
The RIPK1 receptor interacting serine/threonine kinase 1
is a downstream effector of TNFR2 (58), the activation of
which has been shown to protect from aGvHD in a murine
model and act concordantly in human cells in vitro (57). TNF
down-stream signaling and transcription are regulated by TRAFs
(50, 60). Three genes identified by the present study are closely
involved with the NFκB pathway, a central regulator of cytokine
production: NFκB inhibitor β, inhibitor of NFκB2 kinase subunit
β, and NFκB2. Even though NFκB inhibition has not been
successful in human trials, the important role of this pathway
in immunological functions may warrant further studies in
members of its signaling network.
The biologically active form of vitamin D, 1,25-
dihydxoyvitamin D3, has been reported to exert beneficial
immunosuppressive modulation via binding to the nuclear VDR
(61). In an HSCT setting, vitamin D deficiency is considered a
common complaint that may affect the treatment outcome (62).
Genetic polymorphisms of the VDR have been shown to alter
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the immunomodulatory effect of vitamin D (63). Consistent
with these observations, our results suggest a role for VDR in
aGvHD-pathogenesis and present 24 VDR-associated biological
processes. A possible mechanism could involve a positive effect
of vitamin D on telomere length of blood cells directly or via
increasing sex hormone levels, supporting proliferative capacity,
reconstitution, and long-term immunological functionality of
the graft (64–66). This hypothesis is supported by our results
identifying TERT as significantly decreased in severe aGvHD,
and enrichment of GOs involving VDR in hormone metabolism.
eQTL databases may be utilized to detect downstream effects
of variants on gene expression. However, due to the abundance
of cis-eQTL data, generating causal hypotheses for functional
mechanisms of variants has been strongly affected by the
high false-positive rate (43). To overcome this limitation, the
colocalization analysis visualizes the distributions of eQTL and
GWAS signals instead of focusing solely on the lead variants.
Our results suggest colocalization of cis-eQTL events of TRAF6
and the corresponding variants of aGvHD in GWASs, indicating
potential functional importance. TRAF6 has been identified as an
important nuclear factor κB activator and an essential mediator
for the GvHD-suppressing ability of thymic-derived regulatory T
cells (49). Our results showing reduced TRAF6 expression among
aGvHD patients are in consistent with this result. In contrast,
high levels of TRAF6 have been associated with increased GvHD
severity in mice (50). TRAF6 is regulated by miR-146a (67) and
together with TRAF3, which was also implicated by our analysis,
is a downstream effector of TLRmolecules (47) involved in innate
immunity-driven pathogenesis of GvHD (48).
There were several limitations of the study. The HSCT study
cohorts were treated and collected over a long period of time in
different centers, rendering treatment protocols heterogeneous.
The numbers of cases were low in the separate GWASs and
the case-control balance was therefore hardly optimal. Moreover,
the gene expression studies were very heterogeneous in their
study designs and sample collection procedures, and the overall
number of samples was relatively low. This is to some extent
mitigated by the employed meta-analysis method which was
designed for noisy and heterogeneous data (40). Our approach
was also not appropriate for analyzing the complex relationship
between genetic variants implicated by GWAS and expression of
the corresponding genes. To determine the effect directions of
gene expression for GWASs, a transcriptome-wide association
study method (68) would be required, but this could not be
pursued here due to lack of appropriate reference material. This
approach could be improved in future studies by using larger
gene expression data set withmore shared genetic variants.While
the data we used were from Caucasian populations, it would be
important to extend these analyses into other populations. Single
nucleotide polymorphisms may vary among the populations
which may impact the gene-level summary of the GWASs or
regulation of gene expression.
We obtained no results for cGvHD, which may be due
to the smaller number of available studies or lack of strong
genetic component in this condition. We recently reported
that the severity of cGvHD is associated with the overall
immunogenetic differences between HSCT pairs (22); hence, its
genetic background may differ from that of aGvHD.
We conclude that the meta-analysis of varied data types and
populations identified common gene-level effects underlying the
development of acute GvHD. As our approach was able to
discover several previously known genes and immunologically
relevant functional categories, it may be applied in different
setting and to other data types to help identify novel genes
and pathways.
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